Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
Primary Purpose
Diabetic Gastroparesis
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
IW-9179
Matching Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Diabetic Gastroparesis
Eligibility Criteria
Inclusion Criteria:
- Patient is a male or non-pregnant, non-breastfeeding female, and is age 18 years or older at the time of the Screening Visit.
- Patient has a confirmed diagnosis of type 1 or type 2 diabetes mellitus.
- Patient has a diagnosis of DGP with no history or evidence of mechanical obstruction, symptoms for at least 3 consecutive months preceding the Screening Visit, and delayed gastric emptying of solids documented within 2 years of the Screening Visit.
- Patient has a normal EGD either during the Screening Period or within 2 years of the Screening Visit, with no evidence of structural or organic disease that may explain the patient's gastroduodenal symptoms.
- Patient is compliant with eDiary completion.
- Patient agrees to refrain from making any new, major lifestyle changes.
- Patient is fluent and literate in English.
Exclusion Criteria:
- Patient has a history or current symptoms of any organic or structural disease that, in the opinion of the investigator, can cause abdominal pain or discomfort and may confound the assessment of DGP symptoms.
- Patients with rumination syndrome, cyclic vomiting syndrome, anorexia nervosa, or bulimia.
- Patient is currently using a gastric electric stimulator or has had endoscopic pyloric injections of botulinum toxin within the 6 months prior to the Screening Visit.
- Patient has been hospitalized within the 2 months prior to the Screening Visit for uncontrolled diabetes mellitus, DGP, or associated malnutrition.
- Patient reports significant diarrhea during the four weeks prior to the Screening Visit, or more than 2 days during either week of the Pretreatment Period.
- Patient has had surgery of the GI tract any time before the Screening Visit, an appendectomy or cholecystectomy during the 3 months before the Screening Visit, non-GI surgery of the abdomen, pelvis, or retroperitoneal structures during the 6 months, or other major non-GI surgery during the 30 days before the Screening Visit.
- Patient has a history of cancer (resected basal cell or squamous cell carcinoma of the skin is acceptable).
Sites / Locations
- Ironwood Investigational Site
- Ironwood Investigational Site
- Ironwood Investigational Site
- Ironwood Investigational Site
- Ironwood Investigational Site
- Ironwood Investigational Site
- Ironwood Investigational Site
- Ironwood Investigational Site
- Ironwood Investigational Site
- Ironwood Investigational Site
- Ironwood Investigational Site
- Ironwood Investigational Site
- Ironwood Investigational Site
- Ironwood Investigational Site
- Ironwood Investigational Site
- Ironwood Investigational Site
- Ironwood Investigational Site
- Ironwood Investigational Site
- Ironwood Investigational Site
- Ironwood Investigational Site
- Ironwood Investigational Site
- Ironwood Investigational Site
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Placebo Comparator
Experimental
Experimental
Experimental
Arm Label
Placebo BID
IW-9179 QD AM + Placebo QD PM
Placebo QD AM + IW-9179 QD PM
IW-9179 BID
Arm Description
Placebo once in the morning and once in the evening.
IW-9179 once in the morning and placebo once in the evening.
Placebo once in the morning and IW-9179 once in the evening.
IW-9179 once in the morning and once in the evening
Outcomes
Primary Outcome Measures
Exploratory Endpoint - Daily Severity of Patient-reported Diabetic Gastroparesis Symptoms
Secondary Outcome Measures
Full Information
NCT ID
NCT02289846
First Posted
November 10, 2014
Last Updated
December 1, 2016
Sponsor
Ironwood Pharmaceuticals, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT02289846
Brief Title
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
Official Title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients With Diabetic Gastroparesis
Study Type
Interventional
2. Study Status
Record Verification Date
January 2016
Overall Recruitment Status
Completed
Study Start Date
October 2014 (undefined)
Primary Completion Date
December 2015 (Actual)
Study Completion Date
December 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ironwood Pharmaceuticals, Inc.
4. Oversight
5. Study Description
Brief Summary
The objectives of this study are to evaluate the safety of IW-9179 in patients with diabetic gastroparesis (DGP) and the effect of treatment on the cardinal symptoms of DGP.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetic Gastroparesis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
90 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo BID
Arm Type
Placebo Comparator
Arm Description
Placebo once in the morning and once in the evening.
Arm Title
IW-9179 QD AM + Placebo QD PM
Arm Type
Experimental
Arm Description
IW-9179 once in the morning and placebo once in the evening.
Arm Title
Placebo QD AM + IW-9179 QD PM
Arm Type
Experimental
Arm Description
Placebo once in the morning and IW-9179 once in the evening.
Arm Title
IW-9179 BID
Arm Type
Experimental
Arm Description
IW-9179 once in the morning and once in the evening
Intervention Type
Drug
Intervention Name(s)
IW-9179
Intervention Type
Drug
Intervention Name(s)
Matching Placebo
Primary Outcome Measure Information:
Title
Exploratory Endpoint - Daily Severity of Patient-reported Diabetic Gastroparesis Symptoms
Time Frame
Change from baseline: Treatment Period (weeks 1-4) compared with 2-week (baseline) Pretreatment Period
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient is a male or non-pregnant, non-breastfeeding female, and is age 18 years or older at the time of the Screening Visit.
Patient has a confirmed diagnosis of type 1 or type 2 diabetes mellitus.
Patient has a diagnosis of DGP with no history or evidence of mechanical obstruction, symptoms for at least 3 consecutive months preceding the Screening Visit, and delayed gastric emptying of solids documented within 2 years of the Screening Visit.
Patient has a normal EGD either during the Screening Period or within 2 years of the Screening Visit, with no evidence of structural or organic disease that may explain the patient's gastroduodenal symptoms.
Patient is compliant with eDiary completion.
Patient agrees to refrain from making any new, major lifestyle changes.
Patient is fluent and literate in English.
Exclusion Criteria:
Patient has a history or current symptoms of any organic or structural disease that, in the opinion of the investigator, can cause abdominal pain or discomfort and may confound the assessment of DGP symptoms.
Patients with rumination syndrome, cyclic vomiting syndrome, anorexia nervosa, or bulimia.
Patient is currently using a gastric electric stimulator or has had endoscopic pyloric injections of botulinum toxin within the 6 months prior to the Screening Visit.
Patient has been hospitalized within the 2 months prior to the Screening Visit for uncontrolled diabetes mellitus, DGP, or associated malnutrition.
Patient reports significant diarrhea during the four weeks prior to the Screening Visit, or more than 2 days during either week of the Pretreatment Period.
Patient has had surgery of the GI tract any time before the Screening Visit, an appendectomy or cholecystectomy during the 3 months before the Screening Visit, non-GI surgery of the abdomen, pelvis, or retroperitoneal structures during the 6 months, or other major non-GI surgery during the 30 days before the Screening Visit.
Patient has a history of cancer (resected basal cell or squamous cell carcinoma of the skin is acceptable).
Facility Information:
Facility Name
Ironwood Investigational Site
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35203
Country
United States
Facility Name
Ironwood Investigational Site
City
Dothan
State/Province
Alabama
ZIP/Postal Code
36305
Country
United States
Facility Name
Ironwood Investigational Site
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85710
Country
United States
Facility Name
Ironwood Investigational Site
City
North Little Rock
State/Province
Arkansas
ZIP/Postal Code
72117
Country
United States
Facility Name
Ironwood Investigational Site
City
Chula Vista
State/Province
California
ZIP/Postal Code
91910
Country
United States
Facility Name
Ironwood Investigational Site
City
Los Angeles
State/Province
California
ZIP/Postal Code
90036
Country
United States
Facility Name
Ironwood Investigational Site
City
Ventura
State/Province
California
ZIP/Postal Code
93003
Country
United States
Facility Name
Ironwood Investigational Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33122
Country
United States
Facility Name
Ironwood Investigational Site
City
Tampa
State/Province
Florida
ZIP/Postal Code
33607
Country
United States
Facility Name
Ironwood Investigational Site
City
Urbana
State/Province
Illinois
ZIP/Postal Code
61801
Country
United States
Facility Name
Ironwood Investigational Site
City
Bastrop
State/Province
Louisiana
ZIP/Postal Code
71220
Country
United States
Facility Name
Ironwood Investigational Site
City
Chesterfield
State/Province
Michigan
ZIP/Postal Code
48047
Country
United States
Facility Name
Ironwood Investigational Site
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Facility Name
Ironwood Investigational Site
City
Great Neck
State/Province
New York
ZIP/Postal Code
11023
Country
United States
Facility Name
Ironwood Investigational Site
City
New York
State/Province
New York
ZIP/Postal Code
10018
Country
United States
Facility Name
Ironwood Investigational Site
City
Poughkeepsie
State/Province
New York
ZIP/Postal Code
12601
Country
United States
Facility Name
Ironwood Investigational Site
City
Greensboro
State/Province
North Carolina
ZIP/Postal Code
27410
Country
United States
Facility Name
Ironwood Investigational Site
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27103
Country
United States
Facility Name
Ironwood Investigational Site
City
Chattanooga
State/Province
Tennessee
ZIP/Postal Code
37421
Country
United States
Facility Name
Ironwood Investigational Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77015
Country
United States
Facility Name
Ironwood Investigational Site
City
Webster
State/Province
Texas
ZIP/Postal Code
77598
Country
United States
Facility Name
Ironwood Investigational Site
City
Ogden
State/Province
Utah
ZIP/Postal Code
84405
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
29079987
Citation
Ervin CM, Reasner DS, Hanlon JT, Fehnel SE. Exploring the Diabetic Gastroparesis Patient Experience: Patient Exit Interviews. Adv Ther. 2017 Dec;34(12):2680-2692. doi: 10.1007/s12325-017-0632-6. Epub 2017 Oct 27.
Results Reference
derived
Learn more about this trial
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
We'll reach out to this number within 24 hrs